Redx has been presented with a commemorative plaque at its HQ at Alderley Park, in recognition of its discovery of pirtobrutinib, the active pharmaceutical ingredient (API) in Eli Lilly's cancer treatment Jaypirca.
A previously announced research collaboration between Gilead Sciences and Arcus Biosciences that was focused on oncology has been expanded to include inflammatory diseases therapies.
A company says it is developing a small molecule drug without major safety issues to treat a growing number of cases of atrial fibrillation, the most common cardiac arrhythmia.
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
Data from the company’s lead fibrosis asset called RXC700 has highlighted multiple opportunities for patients with pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC).
The UK Government has announced plans to allow patients in England to receive prescription medicines directly from pharmacies without the need for a GP appointment.
AARDEX Group has joined forces with other industry companies to partner with a new project from The Digital Medical Society (DiMe) called Extending the Verification, Analytical Validation, and Clinical Validation – or V3+ Framework.
Two contract research organizations working in the clinical trial and research fields have benefited from investment from Iberian private equity firm, Henko Partners.
Xequel Bio has selected Societal CDMO to support the ongoing clinical development of a patented new chemical entity based on its aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.
Vedanta Biosciences has obtained fast track designation from the US Food and Drug Administration (FDA) for its live biotherapeutic VE303, a preventative treatment for recurrent Clostridioides difficile infection (CDI).
As part of a new initiative, the generic manufacturer will boost access to treatments for anxiety and depression across seven new states across the US, potentially reaching more than 650,000 uninsured patients.
The company unveils the creation of the Institute of Human Biology, which will provide efficacy studies of drug candidates using miniature ‘living replicas’ of human tissues and organs.
Cumulus Neuroscience has been given the clearance by the US Food and Drug Administration (FDA) and the company says this will accelerate treatments for neuropsychiatric and neurodegenerative disorders.
Results from a multinational trial of trifluridine/tipracil, known as Lonsurf, with or without bevacizumab in refractory metastatic colorectal cancer (mCRC) have resulted in statistically significantly and clinically meaningful improvements.
A single-agent treatment for patients with relapsed or refractory myelodysplastic neoplasms has shown promising results, including overall survival, in a study.
The Japanese pharmaceutical giant Astellas Pharma has taken over the U.S. company Iveric Bio in a $5.9 billion deal to get hold of its ophthalmology-focused pipeline.
Rich Christie is chief medical officer at AiCure LLC. He is a firm believer in digtal biomarkers and the audio and visual biomarkers that can be captured through a front-facing camera. OSP inteviewed him to find about more about the changing landscape...
Scorpion Therapeutics, a clinical-stage oncology company, has announced that the first patient has been dosed in a phase 1/2 clinical trial of STX-478, its treatment for breast cancer and other solid tumors.
Galapagos NV has announced it has initiated a phase 3 study with small molecule drug filgotinib in patients with the chronic, highly inflammatory condition, active axial spondyloarthritis(AxSpA).
Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight...
A company developing a potential new category of oral therapies based on defined bacterial consortia has made two big announcements this week (April 25).
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.
Symptom improvements have been hailed as ‘very compelling’ after results from a phase 1 study into a combination of drugs to treat myelofibrosis prove positive.
A drug to treat a rare cancer that grows where the esophagus and stomach join has been accepted for review by the China National Medical Products Administration (NMPA).
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
The German and Spanish companies use their relevant expertise in conjunction to provide clients with services spanning from hit generation to pre-clinical development.
Only a few months after being bought out, the CDMO invests in its capabilities with a facility to support drug-device products and sterile fill-finish.
The Institute for Population and Precision Health (IPPH) at the University of Chicago has joined private biotech company, Freenome, to become its partner as part of a study.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
A partnership was announced this week (April 11) between non-profit CureDuchenne and health technology company, PicnicHealth that will provide as much data as possible to researchers while helping patients navigate complex medical systems.
Dutch biopharmaceutical company, Pharming Group PV, has sent its first commercial shipments of a drug to treat a rare, primary immunodeficiency, to the US.
A breakthrough in rectal cancer treatment has been discovered through a collaboration between a cancer intelligence company and the world’s largest and oldest cancer center. It could put an end to the invasive surgery patients may have faced.
OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction...
